Business
Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Application of Dermal Fillers with its Bioneedle Delivery System
- This would be Dermata's first patent, if issued, covering the use of its Bioneedle Delivery System ("BDS") with dermal fillers -- The Company also has
About this update from Dermata Therapeutics, Inc.
[{"type":"text","content":"- This would be Dermata's first patent, if issued, covering the use of its Bioneedle Delivery System (\"BDS\") with dermal fillers -- The Company also has allowed and issued patents in the US, Australia, and Japan covering their BDS with botulinum toxin for the treatment of hyperhidrosis - SAN DIEGO, CA / ACCESS Newswire / April 2, 2026 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) (\"Dermata\" or the \"Company\"), a science-driven leader in dermatologic solutions, today announced the Australian Patent Office has accepted its patent application for its topical dermal filler program utilizing its BDS. The patent, entitled \"Compositions for the treatment of conditions by dermal fillers,\" (Australian Patent Application No. 2020315876) continues to strengthen Dermata's global intellectual property portfolio for its BDS programs. The patent will be automatically issued three months after acceptance unless a third party files an opposition.\"Our receipt of a notice of acceptance for this Australian patent marks a significant milestone in advancing how dermal fillers can be delivered and potentially expands their uses in the aesthetic market,\" said Gerry Proehl, Chairman, President, and CEO of Dermata. \"Instead of traditional injectable applications, we believe topical delivery of dermal fillers opens the door to a wide range of uses, from smoothing fine lines and restoring skin hydration, to enhancing skin barrier function and supporting skin health. With our recent shift to selling direct to skincare professionals, we believe our BDS has the potential to fundamentally transform aesthetic treatments by enabling a non-invasive, topical approach, while expanding access, improving patient comfort, and redefining the aesthetic standard of care. We are excited about the opportunities this innovation creates as we continue to push the boundaries of what's possible in skincare,\" Mr. Proehl concluded.About Bioneedle Delivery SystemBDS is our topical treatment system that utilizes wild-harvested Spongilla lacustris to aid in the intradermal delivery of macromolecules, such as botulinum toxin or dermal fillers, through topical application by a professional. These macromolecules are highly effective and approved for the treatment of multiple aesthetic skin conditions, but typically must be injected, sometimes requiring numerous i...